Add BrightSurf on Google Email

Preliminary results of the JIKI clinical trial against Ebola test the efficacy of favipiravir in reducing mortality in individuals infected by Ebola virus in Guinea

The JIKI clinical trial found encouraging signs of efficacy for favipiravir in individuals with high or moderate viral replication and less severe visceral lesions. In contrast, patients with very high viral loads and serious visceral involvement showed no efficacy from the treatment. These findings have implications for Ebola virus di...

Protein linked to development of asthma

A study published in Journal of Biological Chemistry identifies CCL28 as a key player in inducing asthma pathology even without a viral infection. This finding opens the door for developing potent and specific CCL28 inhibitors to prevent post-viral asthma in young children.

SourceMedical College of Wisconsin·JournalJournal of Biological Chemistry·DateFeb 20, 2015

NIH Ebola study in macaques provides timeframes for post-mortem viral stability

A recent NIH study found that Ebola virus can remain infectious in a body for at least seven days after death, with viral RNA detectable for up to 10 weeks. The research highlights the importance of safe handling practices and suggests oral swabbing as a reliable alternative for obtaining diagnostic samples.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalEmerging Infectious Diseases·DateFeb 12, 2015

Ebola: New studies model a deadly epidemic

Researchers from Arizona State University and Georgia State University model the impact of timely diagnostic testing on Ebola's spread across populations. Early detection provides the opportunity to safely isolate and treat individuals before they become contagious, significantly reducing the number of infected individuals.

SourceArizona State University·JournalThe Lancet Infectious Diseases·DateFeb 5, 2015

The Louis-Jeantet Prize for Medicine

The 2015 Louis-Jeantet Prize for Medicine was awarded to Emmanuelle Charpentier and Rudolf Zechner for their pioneering work on harnessing bacterial immunity to develop genome editing technology, known as CRISPR-Cas9. The prize also recognizes Zechner's contributions to understanding lipid metabolism and its role in various diseases.

SourceEMBO·DateJan 20, 2015

Infection control preparedness measures control avian flu in Hong Kong hospital

In a Hong Kong hospital, proactive infection control measures implemented since March 2013 successfully controlled the spread of Avian flu (A H7N9), with only two patient cases and no staff infections reported. The integrated approach utilized active surveillance, rapid molecular diagnostic testing, and hand hygiene protocols.

SourceSociety for Healthcare Epidemiology of America·JournalInfection Control and Hospital Epidemiology·DateJan 5, 2015

Bats are a possible source of the Ebola epidemic in West Africa

A study published in EMBO Molecular Medicine suggests that contact between humans and virus-infected bats may have originated the Ebola outbreak in West Africa. The researchers found no evidence of larger wildlife being the source of infection, expanding the range of possible Ebola virus sources to insectivorous free-tailed bats.

SourceEMBO·JournalEMBO Molecular Medicine·DateDec 30, 2014

Simeprevir-based therapy offers cost-effective alternative in treatment of hepatitis C

A new study has shown that a simeprevir-based therapy is as effective as the standard of care in treating chronic Hepatitis C virus infection, with fewer adverse events. The study found that simeprevir was well-tolerated and could be a viable alternative for patients who cannot access or afford newer treatment options.

SourceUniversity of Pennsylvania School of Medicine·JournalThe Lancet Infectious Diseases·DateDec 9, 2014

Experts question aspects of certain Ebola guidelines

The authors of a Transfusion commentary argue that forgoing routine lab tests may compromise patients' health more than any reduction in the risk of transmission. Experts recommend implementing well-characterized infection prevention and control recommendations to provide a safe environment for both patients and employees.

SourceWiley·JournalTransfusion·DateDec 1, 2014

Human antibodies produced in DNA-vaccinated cows protect in lethal models of hantavirus

Scientists have developed protective human antibodies using DNA-vaccinated cows, which showed potent neutralizing activity against two types of hantaviruses. The antibodies protected hamsters from lethal disease caused by these viruses, with seven out of eight treated animals surviving without symptoms.

SourceUS Army Medical Research Institute of Infectious Diseases·JournalScience Translational Medicine·DateNov 26, 2014

In full view

Scientists have determined the complete structure of the influenza virus polymerase, a key machine that makes copies of the virus' genetic material and reads out instructions. The high-resolution structure reveals how the polymerase works as a whole, providing new insights into its function and potential targets for drug design.